ClinicalTrials.gg
Not yet recruitingNCT06742905EAGERUpdated Dec 19, 2024

Echo Acquisition Despite Geographic Separation by Replication of Human Movements (EAGER)

An interventional study of Robot-guided echo and Standard echocardiogram in Echocardiography, sponsored by Baker Heart and Diabetes Institute. Not yet recruiting at 1 site in Australia. Per ClinicalTrials.gov, last updated 2024-12-19.

Sponsored by Baker Heart and Diabetes Institute · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Sex
All
01

Study summary

Echocardiography is a cornerstone of modern cardiology management, but access in rural and remote areas is limited. We have developed a robot ("Edler" named after the originator of echocardiography) which enables a sonographer to complete an examination at a distance. This study seeks to compare the images obtained by both methods, the completeness of the exam over a feasible time, and to identify particular components of the exam that are difficult to obtain using the robot.

Read the detailed description

The EAGER study is an effectiveness and feasibility trial of robot -assisted echo.

Patients who have undergone a standard echo will be asked to have a repeat study with a different sonographer, working remotely, obtaining images using the robot. This study is limited to 1 hour and as many views as possible will be obtained. During the study, the remote sonographer and patient are in direct contact over a video link. Another person will be in the room with the patient and the patient will be instructed on the use of a stop switch which will disengage the robot if they feel uncomfortable.

The acquired images will be saved to the imaging cloud and interpreted by an imaging specialist blinded to the original echocardiogram. A side-by-side comparison will be undertaken for each view, and image quality and study completeness will be assessed.

02

Conditions studied

  • Echocardiography

Keywords

  • Echocardiography
03

In context

Lead sponsor

Baker Heart and Diabetes Institute is the lead sponsor of 26 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having a conventional echocardiogram

Exclusion criteria

Exclusion Criteria:

  • Declined consent to undergo both examinations
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Standard echo

    Standard echo exam provided by a sonographer using a standard view template

    Diagnostic Test: Standard echocardiogram

  • Experimental
    Robotic echo

    Robotic echo exam provided by a sonographer using a standard view template

    Diagnostic Test: Robot-guided echo

Interventions

  • Diagnostic testRobot-guided echo

    This echo will be performed by a remote sonographer, though a robot

  • Diagnostic testStandard echocardiogram

    Echocardiogram acquired by a sonographer at the patient's bedside

06

What researchers measure

Primary outcomes

  1. Proportion complete

    Proportion of a standard acquisition protocol obtainable using robotic acquisition over 1 hour

    Time frame: 1 hour

Secondary outcomes

  1. Proportion complete

    Proportion of echo views with the same information provided by conventional echo

    Time frame: 1 hour

  2. Proportion diagnostic features correctly identified by robotic echo

    Proportion diagnostic features correctly identified by robotic echo

    Time frame: 1 hour

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data that underlie the results reported in this project (text, tables, figures and appendices) will be made available.

Supporting information: Study protocol

Time frame: Dates - material will be made available immediately following publication, with no end date.

Access criteria: The authors are pleased to collaborate with other researchers who provide a methodologically sound proposal, to achieve the aims of the approved proposal, including individual participant data meta-analysis. Proposals should be directed to tom.marwick@baker.edu.au. To gain access, data requestors will need to sign a data access agreement.

Data sharing details ↗ · www.baker.edu.au

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2025; primary completion for Dec 2025, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Dec 19, 2024
StartEst.
Jan 15, 2025
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 31, 2025
Last update
Dec 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06742905
Lead sponsor
Baker Heart and Diabetes Institute
Responsible party
Sponsor
First posted
Dec 19, 2024
Start date
Jan 15, 2025 (estimated)
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Dec 19, 2024

Study contacts

Thomas H Marwick, MBBS, PhD, MPH
Contact
tom.marwick@baker.edu.au
0385321550

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion